Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fuxin Han

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|January 18, 2026
MCT1 inhibition remodels the tumor immune microenvironment for enhanced cancer immunotherapyYipeng Zhang, Chun Liu, Fuxin Han, et al.
Iscience|January 15, 2026
Contextualized biomedical language processing enhances ICU survival predictionRui Chen, Yu Cai, Sitong Zhang, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 19, 2025
Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapyFuxin Han, Yuting Lu, Yipeng Zhang, et al.
American Journal of Hematology|March 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin LymphomaFuxin Han, Yadi Zhong, Chuan Tong, et al.
Science Advances|May 8, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cellsYelei Guo, Chuan Tong, Jianshu Wei, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signalingXinran Ma, Yang Zhang, Yao Wang, et al.
Nature Communications|April 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trialChunmeng Wang, Yelei Guo, Fuxin Han, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|January 18, 2026
MCT1 inhibition remodels the tumor immune microenvironment for enhanced cancer immunotherapyYipeng Zhang, Chun Liu, Fuxin Han, et al.
Iscience|January 15, 2026
Contextualized biomedical language processing enhances ICU survival predictionRui Chen, Yu Cai, Sitong Zhang, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 19, 2025
Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapyFuxin Han, Yuting Lu, Yipeng Zhang, et al.
American Journal of Hematology|March 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin LymphomaFuxin Han, Yadi Zhong, Chuan Tong, et al.
Science Advances|May 8, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cellsYelei Guo, Chuan Tong, Jianshu Wei, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signalingXinran Ma, Yang Zhang, Yao Wang, et al.
Nature Communications|April 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trialChunmeng Wang, Yelei Guo, Fuxin Han, et al.
Pageof 2